- Visibility 556 Views
- Downloads 452 Downloads
- Permissions
- DOI 10.18231/j.ijcaap.2019.021
-
CrossMark
- Citation
Efficacy and cost effectiveness comparision between fusidic acid and mupirocin for impetigo
- Author Details:
-
Fazeel Zubair Ahmed *
-
Anusharani M V
Introduction: Impetigo is a contagious skin infection due to S. aureus or S. pyogenes that usually affects children. BNF recommends topical fusidic acid or mupirocin for impetigo. This study compares the efficacy and cost-effectiveness of topical fusidic acid and mupirocin in treatment of impetigo.
Materials and Methods: This was an open label, prospective study done on 100 impetigo patients attending OPD of Viswabharathi General & Teaching Hospital, Kurnool, Andhra Pradesh, India from January 2016 to December 2016. The primary end points were evaluated at the baseline, and after one week of treatment. The end points were: number of lesions, size of the lesions, SSI score and cost to treat a single case. Patients were randomly allocated to two groups – fusidic acid group and mupirocin group. In both groups the test drug was applied locally thrice daily. Statistical analysis was done using student’s paired t test and unpaired t test. p-value of <0>
Results: In fusidic acid group; number of lesions declined from 4.24±1.17 to 0.24±0.82, wound area (cm2) decreased from 3.24±0.95 to 0.34±1.18 and SSI decreased from 2.32±0.47 to 0.14±0.49. While in mupirocin group; number of lesions declined from 4.16±1.11 to 0.14±0.70, wound area (cm2) decreased from 3.45±1.14 to 0.17±0.85 and SSI decreased from 2.44±0.50 to 0.08±0.39. All these changes were statistically significant. Cost to treat one case was INR 46 for fusidic acid and INR 72 for mupirocin.
Conclusion: Mupirocin is marginally more effective than fusidic acid but this difference was not statistically significant. Cost effectiveness of fusidic acid is less than mupirocin.
Keywords: Fusidic acid, Mupirocin, Impetigo, Cost-effectiveness, Efficacy, Comparison.
References
- Koning S, VD Sande R, Verhagen AP, Van Suijlekom-Smit LW, Morris AD, Butler CC, et al. Interventions for impetigo. Cochrane Skin Group, editor. Cochrane Database Syst Rev 2012 Jan 18 [cited 2019 Jul 9]; Available from: http://doi.wiley.com/10.1002/14651858.CD003261.pub3
[Google Scholar] - Sladden MJ, Johnston GA. Common skin infections in children. BMJ 2004;329(7457):95–9.
- Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol 2003;42(4):251–5.
- Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163–96.
- Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, et al. The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions. J Invest Dermatol 2014;134(6):1527–34.
- Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician 2007;75(6):859–64.
- Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E et al.. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg 2009;80(3):431–4.
- Feaster T, Singer JI. Topical therapies for impetigo. Pediatr Emerg Care 2010;26(3):222–7; quiz 228–31.
- Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus. J Drugs Dermatol 2010;9(10):1198–
- Hay RJ, Adriaans BM. Bacterial infections. In: Champion RH, Rook A, Wilkinson DS, Ebling FJG, Rook A, editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford ; Malden, MA: Blackwell Science; 1998.
- Joint Formulary Committee. Antibacterial drugs. In: British National Formulary (BNF). London: Pharmaceutical Press;
- Resham J Vasani, Sudhir V Medhekar. Topical 2% mupirocin versus 2% fusidic acid versus 1% nadifloxacin cream in the treatment of superficial bacterial infections of the skin. 5 Indian J Drugs Dermatol 2015;1(1):16–8.
- Koranyi KI, Burech DL, Haynes RE. Evaluation of bacitracin ointment in the treatment of impetigo. Ohio State Med J 1976;72(6):368–70.
- Motswaledi M. Impetigo in children: a clinical guide and treatment options. South Afr Family Pract 2011;53(1):44–6.
- George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Pract 2003;53(491):480–7.
- Jeffrey LT, Britton W, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990;117(5):827–9.
- Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990;144(12):1313–5.
- Gupta V. Clinicoepidemiological study of vesiculobullous disorders in pediatric age group. Indian J Paediatr Dermatol 2015;16(1):9.
- Awal G, Kaur T. A clinico-bacteriological study of pyodermas in pediatric population. Int J Res Dermatol 2018;4(1):29.
- Innes JA, Maxwell SRJ, Skin disease. In: Davidson’s essentials of medicine. Second edition. Edinburgh ; New York: Elsevier; 2016;687–729.
- Lawley LP, McCall CO, Lawley TJ. Eczema, Psoriasis, Cutaneous Infections, Acne, and Other Common Skin Disorders. In: Kasper DL, editor. Harrison’s Princ Int Med 19th edition / editors, Dennis L. Kasper, MD, William Ellery Channing, Professor of Medicine, Professor of Microbiology, Department of Microbiology and Immunobiology, Harvard Medical School, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts [and five others]. New York: McGraw Hill Education; 2015. p. 334–52.
- Matthew J. Sewell, Craig N. Burkhart, Dean S. Morrell. Dermatological Pharmacology. In: Brunton LL, Knollmann BC, Hilal-Dandan R, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. Thirteenth edition. New York: McGraw Hill Medical; 2018;1271–96.
- Koning S. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ 2002;324(7331):203.
- Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, et al. Topical Retapamulin Ointment, 1%, versus Sodium Fusidate Ointment, 2%, for Impetigo: A Randomized, Observer-Blinded, Noninferiority Study. Dermatol 2007;215(4):331–40.
How to Cite This Article
Vancouver
Ahmed FZ, V AM. Efficacy and cost effectiveness comparision between fusidic acid and mupirocin for impetigo [Internet]. IP Int J Compr Adv Pharmacol. 2019 [cited 2025 Oct 13];4(3):100-104. Available from: https://doi.org/10.18231/j.ijcaap.2019.021
APA
Ahmed, F. Z., V, A. M. (2019). Efficacy and cost effectiveness comparision between fusidic acid and mupirocin for impetigo. IP Int J Compr Adv Pharmacol, 4(3), 100-104. https://doi.org/10.18231/j.ijcaap.2019.021
MLA
Ahmed, Fazeel Zubair, V, Anusharani M. "Efficacy and cost effectiveness comparision between fusidic acid and mupirocin for impetigo." IP Int J Compr Adv Pharmacol, vol. 4, no. 3, 2019, pp. 100-104. https://doi.org/10.18231/j.ijcaap.2019.021
Chicago
Ahmed, F. Z., V, A. M.. "Efficacy and cost effectiveness comparision between fusidic acid and mupirocin for impetigo." IP Int J Compr Adv Pharmacol 4, no. 3 (2019): 100-104. https://doi.org/10.18231/j.ijcaap.2019.021